| abstract |
A sagavag that specifically binds to human PSGL-1 is provided herein. Unlike bivalent antibodies, these antibodies include duplexes of two units, and each unit contains two light chain variable (VL) domains and two heavy chain variable (VH) domains. This format allows cross-linking agent / FcR-expressing cell-independent sg antibody to PSGL-1, which shows enhanced potency compared to the bivalent PSGL-1 antibody. These antibodies can be used without limitation in a variety of diagnostic and therapeutic methods, including treatment of T-cell mediated inflammatory diseases, transplantation and transfusion. |